Showing 1 - 5 of 5
In many instances, the ATU programme responds to a public health need by accelerating the availability of new drugs even though this study suggests an impact of the programme on the market access of these drugs for which the standard administrative path is longer than usual. In addition,...
Persistent link: https://www.econbiz.de/10011001555
Hospitals are able to impose the RT for single-brand drugs. However, they are no longer able to negotiate below the RT except for generic drugs. Negotiations take place upstream for setting the RT between the public authorities and the firms. </AbstractSection> Copyright Springer International Publishing AG 2012
Persistent link: https://www.econbiz.de/10011001697
The availability of the Diagnosis Related Group (DRG) system for determining hospital costs in some European countries has encouraged its use in pharmacoeconomic evaluations. The DRG system was developed in the US to provide data for prospective payments for hospitals. However, the financing of...
Persistent link: https://www.econbiz.de/10005404858
Objective: To assess the relationship between severity and progression of illness in Parkinson's disease and the use of healthcare resources. Design and setting: This was a prospective cost-of-illness study conducted in France based on clinical observation over a 6-month period of patients with...
Persistent link: https://www.econbiz.de/10005590382
Objective: To describe the economic impact of age-related macular degeneration (AMD) and to assess its medical and non-medical costs. Design and settings: An observational study was carried out in 105 patients in two French centres in a sample of 105 French patients. All consecutive patients,...
Persistent link: https://www.econbiz.de/10005449065